Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359.


Journal Article

The 24-week extension of AIDS Clinical Trials Group Protocol 359, a study of human immunodeficiency virus (HIV)-infected, indinavir-experienced patients, was designed to study the durability of "salvage" treatment regimens. Patients received saquinavir in combination with either ritonavir or nelfinavir and, in addition, delavirdine, adefovir, or both. Patients who demonstrated a virologic response at weeks 12-16 were eligible to continue therapy in the extension through week 48. Of the 105 eligible subjects who were enrolled in the extension, 86 (82%) completed 48 weeks, and 49 (57%) of those 86 had HIV RNA levels

Full Text

Cited Authors

  • Gulick, RM; Hu, XJ; Fiscus, SA; Fletcher, CV; Haubrich, R; Cheng, H; Acosta, E; Lagakos, SW; Swanstrom, R; Freimuth, W; Snyder, S; Mills, C; Fischl, M; Pettinelli, C; Katzenstein, D

Published Date

  • September 2002

Published In

Volume / Issue

  • 186 / 5

Start / End Page

  • 626 - 633

PubMed ID

  • 12195349

Pubmed Central ID

  • 12195349

Electronic International Standard Serial Number (EISSN)

  • 1537-6613

International Standard Serial Number (ISSN)

  • 0022-1899

Digital Object Identifier (DOI)

  • 10.1086/342681


  • eng